Company: CWAN
Filing Date: 2025-03-20
Form Type: 424B3
Source: 0001193125-25-058975
Chunk: 73

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-20
Form: 424B3
Chunk 73
---
 a “holder of record” as of the record date. Enfusion will have technicians ready to assist Enfusion Stockholders with any technical difficulties they may have accessing the virtual meeting. If Enfusion Stockholders encounter any difficulties accessing the virtual meeting or during the meeting time, Enfusion Stockholders should navigate to http://www.virtualshareholdermeeting.com/ENFN2025SM where a phone number for IT support will be posted. 45

Outstanding Shares as of the Record Date

As of the record date, there were 129,847,448 shares of Enfusion Common Stock and Enfusion Class B Common Stock outstanding and owned by
stockholders (i.e., excluding shares of Enfusion Common Stock held in treasury by Enfusion), held by 7 holders of record. Each share of Enfusion Common Stock and Enfusion Class B Common Stock is entitled to one vote on each matter considered at
the Special Meeting.

Enfusion Stockholders may request an appointment to inspect a complete list of stockholders entitled to vote at the
Special Meeting for any purpose germane to the Special Meeting at Enfusion’s headquarters located at 125 South Clark Street, Suite 750, Chicago, Illinois 60603 during ordinary business hours within ten days prior to the Special Meeting by
sending an email request to investors@enfusion.com.

Shares and Voting of Enfusion’s Directors and Executive Officers

As of the record date, Enfusion directors and executive officers, as a group, owned and were entitled to vote 46,887,683 shares of
Enfusion Common Stock and Enfusion Class B Common Stock, or approximately 36.1% of the outstanding shares of Enfusion Common Stock and Enfusion Class B Common Stock. Enfusion currently expects that these directors and executive officers
will vote their shares in favor of the Merger Agreement Proposal and the Adjournment Proposal, although none of the directors and executive officers, other than Oleg Movchan with respect to the Merger Agreement Proposal and the Adjournment Proposal,
are obligated to do so.

Mr. Movchan is Enfusion’s Chief Executive Officer and a member of the Enfusion Board. As noted above,
pursuant to the Support Agreements, the Significant Stockholders agreed to vote all of the shares of Enfusion Securities held by them (representing in the aggregate approximately 46.4% of the total outstanding shares of Enfusion Common Stock and
Enfusion Class B Common Stock as of the record date) in favor of the Merger Agreement Proposal. See the